 |
43 Diseases |  |
13 Trials |
|
13 Trials |  |
784 News |  |
| 123456789101112» |
- ||| Retrospective data, Journal, Adverse events: Sexual dysfunctions associated with antipsychotic drug intake: a retrospective analysis of the FDA adverse events reporting system (FAERS). (Pubmed Central) - Jan 12, 2025
The pathogenesis of SD does not appear to be limited to specific pathomechanisms and therefore not to specific substances. The differing report distributions by sex and the impact of polypharmacy on the symptoms warrant further investigations.
- || PK/PD data, Journal: Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates. (Pubmed Central) - Jan 8, 2025
The differing report distributions by sex and the impact of polypharmacy on the symptoms warrant further investigations. PBPK models were developed for capmatinib, idelalisib, lenvatinib, zaleplon, ziprasidone, and zoniporide, incorporating in
- || ziprasidone / Generic mfg.
PK/PD data, Journal: Ziprasidone population pharmacokinetics and co-medication effects in Chinese patients. (Pubmed Central) - Nov 21, 2024
This study successfully established and validated a PPK model for ziprasidone in Chinese patients with psychiatric disorders. The model provides a scientific reference for individualized dosing of ziprasidone and holds the potential to optimize treatment strategies, thereby enhancing therapeutic efficacy and safety.
- | clozapine / Generic mfg.
Journal: Analysis of clinical studies on clozapine from 2012-2022. (Pubmed Central) - Nov 21, 2024
Ziprasidone, haloperidol, and aripiprazole showed a positive effect on symptoms when added to clozapine...Ziprasidone and risperidone can also be used well for the treatment of schizophrenia. In the treatment of clozapine-induced hypersalivation and weight gain, some drugs proved to be effective.
- || Clinical, Review, Journal: Cardiac safety of antipsychotic medications in pediatric and adolescent population: a systematic review and pathways for future research. (Pubmed Central) - Nov 18, 2024
Only 10 studies have carefully addressed the effect of antipsychotic medications on QTc among pediatric patients, underscoring the need for further research. Personalized risk assessment and regular cardiac monitoring should be integrated into clinical management of pediatric and adolescent patients receiving antipsychotics to facilitate early detection of repolarization abnormalities and potential intervention.
- | ASP4345 / Astellas
Phase classification: A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication (clinicaltrials.gov) - Nov 11, 2024
P2, N=233, Completed, Sponsor: Astellas Pharma Global Development, Inc.
Personalized risk assessment and regular cardiac monitoring should be integrated into clinical management of pediatric and adolescent patients receiving antipsychotics to facilitate early detection of repolarization abnormalities and potential intervention. Phase classification: P2a --> P2
- | Journal: Effects of six antipsychotic drug treatment regimens on short-term heart rate variability in patients with schizophrenia. (Pubmed Central) - Oct 26, 2024
The effects of clozapine combination and clozapine on HRV were greater than for olanzapine, aripiprazole, ziprasidone or risperidone. Attention should be paid to controlling the dosage of clozapine combination and clozapine and monitoring the patient's electrocardiogram during administration.
- ||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Journal, Adverse events: A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system. (Pubmed Central) - Oct 9, 2024
Antipsychotic-induced hyperprolactinemia was more common in women and middle-aged patients. Clozapine had the shortest onset time in raising prolactin, whereas cariprazine had the longest.
- || Retrospective data, Review, Journal: Can atypical antipsychotics alleviate Deficits in psychosocial impairments in patients with a diagnosis of Borderline Personality? A systematic review and meta-analysis. (Pubmed Central) - Sep 23, 2024
However, the magnitude of the benefit above that of placebo was small and its clinical meaningfulness is thus debatable. More randomised-controlled trials are required.
- ||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Rexulti (brexpiprazole) / Lundbeck, Otsuka
Review, Journal, Adverse events: An updated safety review of the relationship between atypical antipsychotic drugs, the QTc interval and Torsades de Pointes: implications for clinical use. (Pubmed Central) - Sep 20, 2024
Agents such as ziprasidone and iloperidone are significantly more likely to prolong the QTc interval compared to others such as brexpiprazole, cariprazine, olanzapine, and clozapine. A personalized approach using low-risk medications when clinically feasible, and at the lowest efficacious dose, offers a promising path toward safer antipsychotic prescribing.
- || Clinical, Retrospective data, Review, Journal: Efficacy and safety of a Chinese medicine formula Diankuang Mengxing Decoction combined with antipsychotics in the treatment of schizophrenia: A meta-analysis of randomized controlled trials. (Pubmed Central) - Sep 10, 2024
The combination of Diankuang Mengxing Decoction with different antipsychotics can improve the overall prognosis of patients with schizophrenia; Diankuang Mengxing Decoction combined olanzapine, a dosage of 400?mL/d and a duration of 4 weeks/30 days being the best in this regard, by alleviating the symptoms and diminishing the disorder's adverse effects. To build on this work, more large-sample, multi-center, and high-quality clinical studies in the future would help to further validate our findings.
- | bupropion / Generic mfg., ziprasidone / Generic mfg.
Journal: Transport and inhibition mechanisms of the human noradrenaline transporter. (Pubmed Central) - Aug 21, 2024
Additionally, bupropion and ziprasidone stabilize NET in its inward-facing state, but they have distinct binding pockets. These structures define the mechanisms governing neurotransmitter transport and non-competitive inhibition in NET, providing a blueprint for future drug design.
- olanzapine / Generic mfg.
Acute Pancreatitis Secondary to Olanzapine-Induced Hypertriglyceridemia: A Case Report (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_638;
Patient was also advised to discontinue cocaine and dulaglutide...Despite these associations, olanzapine's role in pancreatitis can be complex, influenced by patient-specific factors like pre-existing hypertriglyceridemia. Discontinuation often resolves pancreatitis without recurrence, emphasizing careful monitoring and tailored management in affected individuals.
- ||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Rexulti (brexpiprazole) / Lundbeck, Otsuka
Journal, Adverse events, Real-world evidence, Real-world: Characteristics of eye disorders induced by atypical antipsychotics: a real-world study from 2016 to 2022 based on Food and Drug Administration Adverse Event Reporting System. (Pubmed Central) - Aug 19, 2024
In terms of the types of adverse events, our study found that aripiprazole was associated with 28 types of ocular adverse events, followed by quetiapine. Clozapine was only associated with two types of ocular adverse events.
- || olanzapine / Generic mfg., ziprasidone / Generic mfg.
Clinical, Retrospective data, Journal: Evaluation of Clinical Correlation between Insulin Resistance and Antipsychotic Drug Therapy in Patients with Schizophrenia. (Pubmed Central) - Aug 12, 2024
Treatment with olanzapine and ziprasidone improves clinical symptoms in patients with schizophrenia, but increases the risk of insulin resistance. The metabolic side effects of olanzapine are more pronounced.
- Antipsychotic Prescriptions Among Nursing Home Residents with Parkinson's Disease in the End-of-Life Period (Poster Hall (Exhibit Hall A)) - Aug 9, 2024 - Abstract #MDSCongress2024MDS_Congress_1065;
Nursing home residents are more likely than community-dwelling residents with PD to be diagnosed with psychosis and prescribed potentially inappropriate antipsychotics in the last 6 months of life. These data may reflect poor prescribing practices in US nursing homes and warrants further investigation.
- paroxetine / Generic mfg., ziprasidone / Generic mfg.
Pharmacokinetic Intersections in Geriatric Neuropharmacology: A Parkinson's Disease Case Study with Concomitant Refractory Major Depressive Disorder (Poster Hall (Exhibit Hall A)) - Aug 9, 2024 - Abstract #MDSCongress2024MDS_Congress_608;
It emphasizes the critical need for physicians to possess acute awareness of complex pharmacokinetic interactions, championing the ethos of interdisciplinary collaboration to preempt adverse drug interactions. This discourse significantly enriches the conversation on refining neuropharmacological approaches, with a paramount focus on patient safety and optimizing treatment outcomes in the delicate nature of geriatric patient care.
- | haloperidol / Generic mfg.
Journal: Comparison of intramuscular haloperidol and other short-acting injectable antipsychotics for management of acute agitation in an adult inpatient psychiatry unit. (Pubmed Central) - Aug 6, 2024
Whereas the effectiveness at 2 hours was not significantly different between groups, patients who received haloperidol were more likely to experience adverse events and were more often subjected to polypharmacy with benzodiazepines and/or diphenhydramine. This study further supports the use of olanzapine and ziprasidone for acute agitation in patients hospitalized in inpatient psychiatry.
- | Trial completion date: MAIA: Maternal And Infant Antipsychotic Study (clinicaltrials.gov) - Aug 5, 2024
P=N/A, N=200, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
This study further supports the use of olanzapine and ziprasidone for acute agitation in patients hospitalized in inpatient psychiatry. Trial completion date: Aug 2027 --> Dec 2027
- | clomipramine / Generic mfg., ziprasidone / Generic mfg.
Journal: Tricyclic Antidepressant and Antipsychotic Toxicity: Clomipramine and Ziprasidone Overdose. (Pubmed Central) - Aug 2, 2024
In conjunction with the local poison control center, progression of the clinical toxidrome was anticipated, aggressively managed, and successfully treated. This case highlights the dangers of significant TCA toxicity, peak onset of toxicity within six hours, and the amplification of clinical toxidromes with co-ingestions.
- ||| haloperidol / Generic mfg., ziprasidone / Generic mfg.
P3 data, Journal: Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial. (Pubmed Central) - Aug 1, 2024
P3
In delirious, critically ill patients, neither haloperidol nor ziprasidone had a significant effect on cognitive, functional, psychological, or quality-of-life outcomes among survivors. Our findings, along with insufficient evidence of short-term benefit and frequent inappropriate continuation of antipsychotics at hospital discharge, indicate that antipsychotics should not be used routinely to treat delirium in critically ill adults.
- | lithium carbonate ER / Generic mfg., iloperidone / Generic mfg.
Journal: Iloperidone (Fanapt) - a new indication for bipolar disorder. (Pubmed Central) - Jul 15, 2024
Our findings, along with insufficient evidence of short-term benefit and frequent inappropriate continuation of antipsychotics at hospital discharge, indicate that antipsychotics should not be used routinely to treat delirium in critically ill adults. No abstract available
- | Caplyta (lumateperone) - Intra / Cellular Therapies
New P3 trial: Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. (clinicaltrials.gov) - Jul 1, 2024
P3, N=80, Recruiting, Sponsor: Louisiana State University Health Sciences Center Shreveport
- | Journal: Contribution of copy number variants on antipsychotic treatment response in Han Chinese patients with schizophrenia. (Pubmed Central) - Jun 13, 2024
No abstract available Copy number variants contributed to poor APD efficacy and synaptic pathway involved in neurotransmitter was highlighted.
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Review, Journal: An overview of the efficacy and safety of brexpiprazole for the treatment of schizophrenia in adolescents. (Pubmed Central) - Jun 12, 2024
For brexpiprazole, the paucity of data in adolescents relegates it to second-line agent. More research on brexpiprazole is needed to delineate its relative role in the management of adolescent schizophrenia.
- || Review, Journal: Determining Ideal Management for Patients With Coexisting Prolactinomas and Psychiatric Symptoms: A Systematic Review. (Pubmed Central) - May 31, 2024
If these 2 initial approaches do not yield a significant improvement in symptom management, surgery or radiation therapy may be considered. As patients may respond differently to these therapies, our study still recommends a patient-centered approach.
- | Journal: Evaluation of Anti-Agitation Medication Prescribing Patterns by Age in the Emergency Department. (Pubmed Central) - May 30, 2024
The findings of this study also suggest that the most common agitation etiologies may differ based on patient age. Additional higher-quality studies are needed to further explore acute agitation in older adults.
- | Visken (pindolol) / Novartis
Preclinical, Journal: Evaluation of multitarget drugs on the expression of cocaine-induced locomotor sensitization in male rats: A comparative study. (Pubmed Central) - May 10, 2024
Additional higher-quality studies are needed to further explore acute agitation in older adults. Here we compare the efficacy of mirtazapine (MIR), pindolol (PIN), fluoxetine (FLX), risperidone (RIS), trazodone (TRZ), ziprasidone (ZPR), ondansetron (OND), yohimbine (YOH), or prazosin (PRZ), to reduce long-term cocaine-induced locomotor activity and the expression of cocaine-induced locomotor sensitization in rats...After each administration, locomotor activity for each animal was recorded for 30
- ||| Journal, Adverse events: Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia. (Pubmed Central) - May 7, 2024
While overall sex differences were limited across efficacy and tolerability for antipsychotic treatment, there were some specific findings with risperidone. Further examination of sex differences within antipsychotic trials will be important to improve efficacy and reduce adverse responses across as well as individualising care for people with schizophrenia.
- || Nuplazid (pimavanserin) / Acadia Pharma
Review, Journal: Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine. (Pubmed Central) - Apr 29, 2024
Pimavanserin, a selective serotonin inverse agonist, avoids receptor-related side effects but has been linked to corrected QT (QTc) interval prolongation, while quetiapine has been reported to be associated with an increased risk of mortality. This review aims to analyze the benefits, risks, and mechanisms of action of antipsychotic medications to assist clinicians in making informed decisions and enhance patient care.
- | aripiprazole / Generic mfg., haloperidol / Generic mfg., ziprasidone / Generic mfg.
Journal: New role of platelets in schizophrenia: predicting drug response. (Pubmed Central) - Apr 15, 2024
Given PLTc's easy measurement and clinical relevance, it warrants increased attention from psychiatrists. ChiCTR-TRC-10000934.
- | ziprasidone / Generic mfg.
Journal: Cognitive Effects of Reducing First-Generation Antipsychotic Dose Compared to Switching to Ziprasidone in Long-Stay Patients with Schizophrenia. (Pubmed Central) - Apr 13, 2024
In patients with severe chronic schizophrenia, ziprasidone had a non-significant and very modest beneficial effect on cognitive function compared with FGA dose reduction. Larger trials are needed to further investigate this effect.
- | lithium carbonate ER / Generic mfg.
Journal: Drugs for bipolar disorder. (Pubmed Central) - Apr 9, 2024
Larger trials are needed to further investigate this effect. No abstract available
- Seizalam (midazolam intramuscular) / Pfizer
A comparison of droperidol 5 mg and 10 mg for acute agitation in the emergency department. () - Mar 18, 2024 - Abstract #ISICEM2024ISICEM_1023;
Droperidol 10 mg for treatment of acute agitation may not result in less rescue sedation needed or shorter ED lengths of stay compared to droperidol 5 mg. However, this may be in part due to baseline levels of agitation resulting in provider preference when selecting droperidol doses.
- | ziprasidone / Generic mfg.
Journal: Psychopharmacotherapy of mixed affective states in bipolar disorder (Pubmed Central) - Mar 15, 2024
On the example of a patient with a mixed affective episode within the framework of bipolar affective disorder, the clinical features of this psychopathological condition, the difficulties of diagnosis and selection of therapy in mixed states are presented. The use of the modern atypical antipsychotic ziprasidone in this category of patients is argued.
- Potentially Inappropriate Prescribing Practices Among Nursing Home Residents with Parkinson's Disease in the End-of-life Period (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3907;
Nursing home residents are more likely than community-dwelling residents with PD to be diagnosed with dementia and prescribed PIMs in the last 6 months of life. These data may reflect inappropriate prescribing practices in US nursing homes, and their association with 6-month mortality warrants further investigation.
- Peripheral Synucleinopathy in Patients Diagnosed with Drug-induced Parkinsonism with Normal Dopamine Transporter Imaging (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_2462;
Causative drugs included aripiprazole (6), olanzapine (2), amiodarone (2), valproate (1), ziprasidone (1), risperidone (1), or combination of drugs (4). Skin biopsy for P-SYN may be more sensitive than DAT scan in identifying DIP patients who may be at risk for developing PD or some other synucleinopathy.
- | Journal: Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022. (Pubmed Central) - Feb 20, 2024
Tiotixene, pimozide and quetiapine were associated with a higher risk of reporting a WDS whereas this risk was lower with chlorpromazine, clozapine and fluphenazine. We could not address the issue of withdrawal psychosis, withdrawal dyskinesia, rebound psychosis or supersensitivity psychosis due to the lack of specific WHO medDRA coded terms to identify potential cases.
- ||||||||| lithium carbonate ER / Generic mfg.
Trial termination, HEOR: Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=1037352, Terminated, Sponsor: University of New Mexico
We could not address the issue of withdrawal psychosis, withdrawal dyskinesia, rebound psychosis or supersensitivity psychosis due to the lack of specific WHO medDRA coded terms to identify potential cases. Completed --> Terminated; Per PI, this study is not a clinical trial and was inadvertently entered in the system
- || haloperidol / Generic mfg., ziprasidone / Generic mfg.
Clinical, Journal: Antipsychotics and the QTc Interval During Delirium in the Intensive Care Unit: A Secondary Analysis of a Randomized Clinical Trial. (Pubmed Central) - Jan 26, 2024
P3
The findings of this trial suggest that daily QTc interval monitoring during antipsychotic use may have limited value in patients in the ICU with normal baseline QTc and few risk factors for QTc prolongation. ClinicalTrials.gov Identifier: NCT01211522.
- | haloperidol / Generic mfg., ziprasidone / Generic mfg.
Journal: Effects of Ziprasidone or Haloperidol on Theory of Mind in Patients With Schizophrenia: A 16-week Pilot Trial. (Pubmed Central) - Jan 20, 2024
ClinicalTrials.gov Identifier: NCT01211522. The findings of this study suggest that ziprasidone could improve ToM and might be superior to haloperidol for improving complex ToM as well as personal and social functioning in patients with schizophrenia.
- | Trial completion date, Trial primary completion date: MAIA: Maternal And Infant Antipsychotic Study (clinicaltrials.gov) - Jan 1, 2024
P=N/A, N=200, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- || Review, Journal: Risk Stratification of QTc Prolongation in Critically Ill Patients Receiving Antipsychotics for the Management of Delirium Symptoms. (Pubmed Central) - Dec 22, 2023
In intensive care settings, we recommend regular ECG monitoring, using a linear regression formula to correct for heart rate. If substantial QTc prolongation (eg, QTc?>?500 msec) is present, a change in pharmacologic treatment can be considered, though a particular medication may still be warranted if the risks of discontinuation (eg, extreme agitation, removal of invasive monitoring devices) outweigh the risks of arrhythmias.
- || Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Review, Journal: Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antipsychotics. (Pubmed Central) - Nov 29, 2023
If substantial QTc prolongation (eg, QTc?>?500 msec) is present, a change in pharmacologic treatment can be considered, though a particular medication may still be warranted if the risks of discontinuation (eg, extreme agitation, removal of invasive monitoring devices) outweigh the risks of arrhythmias. Molecular neuroimaging studies serve as a strong tool for defining target ranges for antipsychotic drug treatment and directing therapeutic drug monitoring.
- ||| Trintellix (vortioxetine) / Lundbeck, Takeda
Journal, Adverse events: Drugs and bruxism: a study in the World Health Organization's pharmacovigilance database. (Pubmed Central) - Nov 27, 2023
A signal was also described for oxybate sodium and metoclopramide. For antidepressants, a negative association was found between ROR values and NET (norepinephrine transporter) but not SERT (serotonin transporter) pKi values, suggesting this ADR is more closely linked to norepinephrine than serotonin reuptake inhibition.
- || Retrospective data, Review, Journal: Efficacy and Tolerance of Antipsychotics Used for the Treatment of Patients Newly Diagnosed with Schizophrenia: A Systematic Review and Meta-Analysis. (Pubmed Central) - Nov 21, 2023
Olanzapine caused less discontinuation than quetiapine; quetiapine caused less discontinuation than ziprasidone, aripiprazole and haloperidol; ziprasidone caused less discontinuation than quetiapine, aripiprazole and haloperidol; aripiprazole caused less discontinuation than quetiapine, ziprasidone and olanzapine and olanzapine caused less discontinuation than ziprasidone and haloperidol (p < 0.05). It was concluded that individual patient clinical response, tolerance to side effects and life-threatening side effects remain the most reliable basis for selecting and continuing the use of APD.
- | Enrollment open: MAIA: Maternal And Infant Antipsychotic Study (clinicaltrials.gov) - Nov 13, 2023
P=N/A, N=200, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
It was concluded that individual patient clinical response, tolerance to side effects and life-threatening side effects remain the most reliable basis for selecting and continuing the use of APD. Not yet recruiting --> Recruiting
- || Serlect (sertindole) / Lundbeck, Abbott
Review, Journal: The cellular mechanism of antipsychotic-induced myocarditis: A systematic review. (Pubmed Central) - Nov 13, 2023
Not yet recruiting --> Recruiting Antipsychotics examined in the included studies included clozapine (n
- Second-Generation Antipsychotics and VTE Risk (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_5444;
Antipsychotics examined in the included studies included clozapine (n Events were then narrowed further to include only those associated with a single second-generation antipsychotic
- || Nuplazid (pimavanserin) / Acadia Pharma
Retrospective data, Review, Journal: Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis. (Pubmed Central) - Oct 23, 2023
In patients with PDP, pimavanserin and clozapine demonstrated significant improvement in psychosis without affecting motor function. With quetiapine being associated with a significant decline in cognition and despite not impairing motor function, our findings suggest that it should be avoided in patients with PDP and reduced cognitive abilities.